GP Remote Consultation to Reduce Opioid Prescribing

NCT05276089 | Unknown

• 1 other identifier: NU-010572
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 2

Brief Summary

Opioid prescribing rates are high in the North East and North Cumbria region of England. The COVID-19 pandemic has interrupted the existing regional programme that aims to reduce the use of opioid medications, and also prescribing is likely to have increased during the lockdown. Thus, it has become increasingly challenging for primary care to dedicate sustained clinical time to tackle this complex issue with patients, who may also be reluctant to seek help. A video messaging intervention based upon a GP consultation was developed to remotely explain the rationale for opioid reduction and facilitate self-initiation of support. The short video suitable for smartphone viewing is messaged using a two-way communication system. Patients can watch the video and request additional support by replying with a simple text or email response. This enables efficient delivery of a discrete offer of help to at risk individuals who often avoid service contact. The aim of this study is to evaluate the potential benefits, risks and economic consequences of 'at scale' implementation. This study will be a mixed methods study comprising of a quasi-experimental non-randomised before-and-after study and qualitative interviews. In the first phase, the intervention arm will comprise 50 GP practices in the region using System 1 who will deliver the video to their patients. The control arm comprises 50 practices in the region using EMIS who will continue care as usual. The unit of analysis is the GP practice, with no individual-level quantitative data collected. Monthly practice level data will be accessed and followed up for 6 months. A general linear model will be used to estimate the association between the exposure (video message vs. control) and the outcome (opioid prescribing). In the second phase, semi-structured interviews will be undertaken remotely with purposively selected participants including patients who received the video and health professionals involved in sending out the videos. These interviews will be audio recorded with participants' consent, transcribed and analysed thematically. As well as evidence and rapid insights to inform the potential accelerated implementation of the intervention within the Integrated Care System, this study will provide evidence that could underpin the future adoption of the intervention into wide scale clinical management that can be disseminated as a future national programme via the Academic Health Science Network.

Conditions

Opioid Use

Outcome Measures

Primary Outcomes (1)

• Change from baseline line opioids analgesics assessed as Average Daily Quantity (ADQ)/1000 Specific Therapeutic group Age-sex Related Prescribing Unit (STAR PU) at 6 months

  This is a practice level data collected monthly by electronic Prescribing Analysis and Costs (ePACT2) by North of England Commissioning Support Unit (NECS). NECS has agreed to support data requests and access.

  Up to 7 months

Secondary Outcomes (6)

• Change from baseline line all opioids (adding in compound analgesics) Average Daily Quantity (ADQ)/1000 Specific Therapeutic group Age-sex Related Prescribing Unit (STAR PU)at 6 months

  Up to 7 months

• Change from baseline line gabapentinoid (gabapentin&pregabalin) Average Daily Quantity (ADQ)/1000 Specific Therapeutic group Age-sex Related Prescribing Unit (STAR PU) at 6 months

  Up to 7 months

• Change from baseline line high dose opioid items as percentage regular opioids

  Up to 7 months

• The number (proportion) of individuals who were followed up by the practice within 1 month of choosing Options 1) and 3), will be quantified being sent the message.

  Up to 7 months

• The percentage of the video watched by participants who were sent the video

  Up to 7 months

Study Arms (2)

Intervention arm

EXPERIMENTAL

A total of 50 practices who use System 1 will be in the intervention arm to send out the video to their eligible patients.

Behavioral: Video message

Control arm

NO INTERVENTION

50 practices who use EMIS will be in the control arm to deliver care as usual

Interventions

Video message BEHAVIORAL

The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses: 1. I would like to reduce my opioid medication with support. 2. I understand this video but I want to continue my current dose. 3. I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information.

Intervention arm

Eligibility Criteria

• Age: 18 Years - 110 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• adults (aged 18 or over)
• registered with a mobile phone number at practices
• regularly taking opioids for more than 90 days or at a dose equivalent to \> 100 mg of codeine a day (this varies for each opioid medication) using electronic records

You may not qualify if:

• if they are coded cancer or palliative care.

Sponsors & Collaborators

• Dr Yu Fu: lead
• Teesside University: collaborator
• NIHR Applied Research Collaboration for North East and North Cumbria: collaborator
• North East Academic Health Science Network: collaborator

Study Sites (2)

LCRN

Newcastle, United Kingdom

Location

LCRN

Newcastle, United Kingdom

Location

Related Publications (1)

• Fu Y, Allen B, Batterham AM, Price C, Jones N, Martin D, Hex N, Maule E, Finch T, Newton JL, Ryan CG. Digitally deployed, GP remote consultation video intervention that aims to reduce opioid prescribing in primary care: protocol for a mixed-methods evaluation. BMJ Open. 2023 Feb 6;13(2):e066158. doi: 10.1136/bmjopen-2022-066158.

  PMID: 36746541 DERIVED

Central Study Contacts

Yu Fu, PhD

CONTACT

07809759652; yu.fu@newcastle.ac.uk

Julia Newton, PhD

CONTACT

07732628443; Julia.Newton@ahsn-nenc.org.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 21, 2022
• First Posted: March 11, 2022
• Study Start: February 1, 2023
• Primary Completion: June 1, 2023
• Study Completion: June 1, 2023
• Last Updated: November 3, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

GB (2)